Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474812 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00474812: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00474812 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00474812, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.
Primary Outcome
From the date of onset of treatment to the date of death and to the date of last follow-up for those still alive, assessed up to 24 months
Interventions
- DRUG dasatinib
- PROCEDURE laboratory biomarker analysis
- PROCEDURE physiologic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2007-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT00474812 record still lists
NCT00474812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which dasatinib is the first listed.
NCT00474812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00474812 about?
NCT00474812 is a clinical study titled "Dasatinib in Treating Patients With Metastatic Pancreatic Cancer". Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.
What is the current status of trial NCT00474812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2007-05. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00474812?
The interventions under investigation include: dasatinib (DRUG), laboratory biomarker analysis (PROCEDURE), physiologic testing (PROCEDURE).
Who is sponsoring clinical trial NCT00474812?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00474812's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia